E, T., & NW, C. (2022). Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus aureus Bacteremia: A Focused Literature Review and Call to Action. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(8), 1457. https://doi.org/10.1093/cid/ciac363
Chicago Style (17th ed.) CitationE, Thottacherry, and Cortés-Penfield NW. "Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus Aureus Bacteremia: A Focused Literature Review and Call to Action." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 75, no. 8 (2022): 1457. https://doi.org/10.1093/cid/ciac363.
MLA (9th ed.) CitationE, Thottacherry, and Cortés-Penfield NW. "Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus Aureus Bacteremia: A Focused Literature Review and Call to Action." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 75, no. 8, 2022, p. 1457, https://doi.org/10.1093/cid/ciac363.
